- Home
- PRE vs UNCY Comparison
PRE vs UNCY Comparison
Compare PRE & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRE | UNCY |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.3M | 121.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRE | UNCY |
|---|---|---|
| Price | $16.56 | $5.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $32.00 | ★ $44.50 |
| AVG Volume (30 Days) | 137.5K | ★ 394.5K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,079,000.00 | N/A |
| Revenue This Year | $219.28 | N/A |
| Revenue Next Year | $124.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 201.54 | N/A |
| 52 Week Low | $3.10 | $3.71 |
| 52 Week High | $17.99 | $11.00 |
Technical Indicators
Market Signals| Indicator | PRE | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 63.85 | 50.83 |
| Support Level | $14.02 | $6.31 |
| Resistance Level | $15.70 | $6.95 |
| Average True Range (ATR) | 1.18 | 0.42 |
| MACD | 0.18 | -0.08 |
| Stochastic Oscillator | 94.44 | 13.68 |
Price Performance
Historical ComparisonAbout PRE Prenetics Global Limited
Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.